Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
others require injection
The cardiovascular outcome studies under way for incretin-based medications (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation [LEADER] with liraglutide [clinicaltrials.gov, NCT01179048] [27], Exenatide Study of Cardiovascular Event Lowering [EXCSEL] with exenatide once weekly [NCT01144338], Trial Evaluating Cardiovascular Outcomes with Sitagliptin [TECOS] with sitagliptin [NCT00790205], Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus [SAVOR-TIMI 53] with saxagliptin [NCT01107886] [28], and Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA) with linagliptin [NCT01243424]) will help in that respect, although the number of events from a single trial will probably be too low for definite answers
With its micro-dosing approach, users can expect effective results with minimal side effects
These may be temporary and resolve without any medication changes
Why the literature stopped in the early 1990s DSIP research has a distinctive shape: a burst of activity from roughly 1977 to 1992, then near-silence
These are supported by decades of outcome data
US$ 28.65
US$ 22.07
US$ 22.20
US$ 29.96
US$ 26.96
US$ 24.26
